



Biotech Daily

Wednesday February 3, 2021

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: PARADIGM UP 12%; RESONANCE DOWN 6%**
- * **BOTANIX: BTX1801 'ERADICATES STAPHYLOCOCCUS AUREUS'**
- * **PARADIGM: ZILOSUL 'REDUCES OA PAIN 50%'**
- * **ANTEOTECH: ELLUME ANTOBIND CONTRACT SECURE**
- * **RECCE RECEIVES \$926k FEDERAL R&D TAX INCENTIVE, TOTAL \$1.6m**
- * **ANATARA RECEIVES \$888k FEDERAL R&D TAX INCENTIVE**
- * **AUSTRALIAN ETHICAL DILUTED TO 10% OF CYCLOPHARM**
- * **ALLIANZ TAKES 8% OF STARPHARMA**

MARKET REPORT

The Australian stock market was up 0.92 percent on Wednesday February 3, 2021, with the ASX200 up 62.0 points to 6,824.6 points. Twenty-one of the Biotech Daily Top 40 stocks were up, eight fell and 11 traded unchanged. All three Big Caps were up.

Paradigm was the best, up 29 cents or 11.65 percent to \$2.78, with 3.98 million shares traded.

Actinogen climbed 10.5 percent; Impedimed and Neuren improved more than nine percent; Alterity, Compumedics, Kazia and Universal Biosensors were up more than five percent; Amplia and Avita climbed more than three percent; Antisense, Cochlear, CSL, Cynata, Mesoblast, Nanosonics and Telix rose more than two percent; Immutep, Orthocell, Pro Medicus, Resmed and Starpharma were up more than one percent; with Cyclopharm and Volpara up by less than one percent.

Resonance led the falls, down one cent or 5.6 percent to 17 cents, with 1.4 million shares traded.

Prescient fell 4.55 percent; Patrys lost 3.7 percent; Imugene shed two percent; Genetic Signatures and Pharmaxis were down more than one percent; with Opthea and Polynovo down by less than one percent.

BOTANIX PHARMACEUTICALS

Botanix says that a 66-patient, phase IIa trial shows that BTX1801 can eradicate *Staphylococcus aureus* bacteria from the nose of healthy participants.

Botanix said the randomized, vehicle-controlled, double-blind study of its synthetic cannabidiol BTX1801 gel and ointment showed both formulations to be safe and well-tolerated, with efficacy against *Staphylococcus aureus* bacteria, compared to placebo. The company said participants in three cohorts of 22 patients received either placebo or BTX1801 as a gel or ointment for five days.

Botanix said that at day-7, two days after treatment completion, *Staphylococcus aureus* was eradicated in 76.2 percent of multiple samples from the ointments group and 68.8 percent in gel group samples, compared to 27.8 percent in the placebo cohort samples. The company said that at day-12, *Staphylococcus aureus* was eradicated in 38.1 percent and 25.0 percent of the remaining ointment group samples and gel group patient samples, respectively, compared to 16.7 percent of the remaining placebo recipient samples. Botanix said that by day 28, or 23 days following treatment, *Staphylococcus aureus* bacteria in the remaining participants were eradicated by 23.8 percent in the ointment group samples and 18.8 percent in the gel group samples, compared to 12.5 percent in the placebo cohort's samples.

The company said "the incidence of adverse events was low, mild in severity and occurred at similar rates across the different treatment groups with no severe events reported".

Botanix executive chair Vince Ippolito said the trial was "the first time that synthetic [cannabidiol] has been shown to have clinical utility as an antimicrobial agent in humans."

"These results support continued development of BTX1801 for the treatment of a variety of infections, in addition to the prevention of post-surgical infections," Mr Ippolito said.

Botanix was up 2.5 cents or 17.2 percent to 17 cents with 79.4 million shares traded.

PARADIGM BIOPHARMACEUTICALS

Paradigm says 89 patients receiving its Zilosul for osteoarthritis under the special access scheme have shown an average pain reduction of 49.6 percent.

Last year, Paradigm said that 76 patients receiving Zilosul, or injectable pentosan polysulphate sodium (PPS) under the Australian Therapeutics Goods Administration special access scheme (SAS) showed an average pain reduction of 47.3 percent, with 40 patients reporting pain reduction of more than 50 percent (BD: Oct 1, 2020).

Today, the company said the pain reduction was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (Womac), a set of standardized questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip, including pain, stiffness, and physical functioning.

Paradigm said 67 of the 89 patients reported a reduction in pain of at least 25 percent and 50 patients reported pain reduction of more than 50 percent.

The company said it was planning a phase III trial of Zilosul for osteoarthritis with the primary endpoint a reduction in pain and function from baseline using the Womac index.

Paradigm chief executive officer Paul Rennie said the company had seen consistent reduction in pain with each group of patients with average Womac pain reduction across the 89-patient cohort being just under 50 percent.

"We are seeing consistent clinically meaningful reduction in pain and improvement in joint function in [osteo-arthritis] patients who have failed to respond to other medications," Mr Rennie said. "It is very important ... that we are seeing real world evidence in subjects with knee [osteo-arthritis] responding in such a positive manner."

Paradigm was up 29 cents or 11.65 percent to \$2.78 with four million shares traded.

[ANTEOTECH, ELLUME](#)

Anteo says it has the capacity to supply its Anteobind for Ellume's immunoassay, in relation to Ellume's US Sars-Cov-2 home test supply deal.

In 2016, Anteo said it had a supply deal with Ellume for a quantum dot detection system combining nano-technology and opto-electronics for immunoassays, which would incorporate Anteo's Anteobind surface coating technology (BD: Oct 28, 2016).

Yesterday, Ellume said the US Government would provide \$US231.8 million (\$A302.8 million) to produce up-to 19 million severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2) home tests a month at full capacity (BD: Feb 1, 2021).

Today, Anteo said it expected that Ellume's requirement for Anteobind would "increase modestly over coming months as they begin to supply the US markets".

Anteo was up 8.5 cents or 85.0 percent to 18.5 cents with 170.8 million shares traded.

[RECCE PHARMACEUTICALS](#)

Recce says it has received \$925,981 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Recce said the rebate related to research and development expenditure for the year to June 30, 2020, taking its total rebate for the period to \$1,566,030.

In October, the company said it received \$640,049 under the Federal Research and Development Tax Incentive program the year to June 30, 2020 (BD: Oct 5, 2020).

Recce fell 2.5 cents or 2.4 percent to \$1.025.

[ANATARA LIFESCIENCES](#)

Anatara says it has received \$888,049 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Anatara said the rebate related to expenditure for the year to June 30, 2020.

Anatara fell one cent or 4.8 percent to 20 cents.

[CYCLOPHARM](#)

The Sydney-based Australian Ethical Investment says its 9,220,165 shares Cyclopharm have been diluted from 11.49 percent to 10.04 percent.

Australian Ethical said it was diluted on February 1, 2021 in Cyclopharm's \$30.0 million placement at \$2.60 a share (BD: Jan 27, 2020).

Cyclopharm was up two cents or 0.7 percent to \$2.75.

[STARPHARMA HOLDINGS](#)

Allianz SE says it has increased its substantial shareholding in Starpharma from 28,632,065 shares (7.11%) to 32,746,474 shares (8.06%).

The Munich, Germany-based Allianz said it bought and sold shares between October 14, 2020 and January 29, 2021 at prices ranging from \$1.27 to \$1.63 a share.

Starpharma was up three cents or 1.9 percent to \$1.625 with 1.96 million shares traded.